Comparison · NCT03463993-836d30ce
Group A vs Group B: Neonatal Outcome - Number of Neonates Diagnosed With Jaundice
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Group A vs Group B: Neonatal Outcome - Number of Neonates Diagnosed With Jaundice. Trial comparisons, record NCT03463993-836d30ce. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03463993-836d30ce
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00446 | 0.000788 | 0.0248 | wilson | |
| Risk in group 2 | 0 | 0 | 0.0166 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00446 | -0.0126 | 0.0248 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Group A than on Group B | 224 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Group A | Participants receive a low dose of Tranexamic acid (10mg/kg) administered slowly over 5 minutes intravenously (iv) 10 minutes prior to skin incision in elective caesarean section with prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby.~Tranexamic Acid: TXA (10mg/kg) solution for injection from the vial will be diluted with 100 - 200ml electrolyte solution such as Normal Saline, Ringers solution, dextrose/water for injection on the same day it is to be used (i.e. when anaesthetist notes the patient has been randomized to receive TXA). Intravenous administration should be at a rate of 100mg or fraction thereof over at least 1 minute - usually at least 5 minutes. Standard practice is to administer over 20 minutes. Administration is to be done at least 10 minutes prior to skin incision.~Oxytocin: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section. | 1 | 224 | OG000 |
| Group 2 | Group B | Participants receive prophylactic oxytocin (5 IU iv) slow administration on delivery of the baby~Oxytocin: 5IU of oxytocin are administered intravenously slowly once the baby has been delivered at caesarean section. | 0 | 227 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Neonatal Outcome - Number of Neonates Diagnosed With Jaundice
- Description
- Number of neonates with clinical jaundice (yellowing of the skin or whites of the eyes)
- Time frame
- From date of delivery of neonate by caesarean section until day 2 post-caesarean section (the date of discharge from hospital) or date of death whichever comes earlier
- Population
- Intention-to-treat population
Source ClinicalTrials.gov
Trial
- Title
- Efficacy of Tranexamic Acid in Preventing Postpartum Haemorrhage After Elective Caesarean Section
- NCT number
- NCT03463993
- Phases
- PHASE3
- Conditions
- Post Partum Hemorrhage
- Interventions
- Tranexamic Acid, Oxytocin
- Lead sponsor
- University of Zimbabwe
- Results first posted
- 2022-04-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03463993?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03463993-836d30ce